ClinicalTrials.gg
TerminatedNCT03325296Updated Feb 24, 2025

Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.

A Phase 2 interventional study of LEO 124249 and Ointment vehicle in Alopecia Areata, sponsored by LEO Pharma. Terminated at 2 sites in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment

Why this study was terminated
Futility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This clinical trial attempts to investigate the efficacy of LEO 124249 ointment in the treatment of alopecia areata on the eyebrows.

02

Conditions studied

  • Alopecia Areata

Browse trials for

03

In context

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

This study's enrollment of 13 is below the median of 50 across 171 interventional studies indexed under Alopecia Areata.

Browse Alopecia Areata studies →

Lead sponsor

LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical unequivocal diagnosis of Alopecia Areata (patchy, univeralis and totalis), on both scalp and eyebrows as assessed by the investigator.
  • Maximal disease duration of current episode of Alopecia Areata on the eyebrows of 3 years at screening.
  • Maximal Alopecia Areata disease duration - defined as years of active disease - in other locations than eyebrows of 10 years at screening.

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis of diffuse type alopecia areata as assessed by the investigator.
  • Any topical, intralesional therapy or procedure applied within 2 cm of the treatment area, within 4 weeks of randomisation, which in the opinion of the investigator, could interfere with the trial assessments. This includes, but is not limited to: , calcineurin inhibitors, calcipotriol, minoxidil, antimicrobials, prostaglandin analogs (e.g. bimatoprost), herbal extracts, topical immunotherapy with allergens or irritants and any laser or phototherapy, and eyebrow tattoo.
  • Any systemic treatment with drugs (e.g. methotrexate, cyclosporine, azathioprine), chloroquin derivatives, corticosteroids (including intralesional treatment outside the trial treatment area), or any other systemic therapy that in the opinion of the investigator could affect hair regrowth, within 4 weeks prior to randomisation.
  • Any biologic medicinal product targeting the immune system within 5 half-lives and minimum 4 weeks prior to randomisation (e.g. anti-TNFα, anti-IL17, anti IL12/23, anti IL-4Rα targeting drugs).
  • Systemic JAK inhibitor Ruxolitinib (Jakafi®/Jakavi®), Tofacitinib (Xeljanz®) at any time prior to randomisation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    LEO 124249 ointment 30 mg/g

    Ointment to be applied on the eyebrow twice daily.

    Drug: LEO 124249

  • Placebo comparator
    LEO 124249 ointment vehicle

    Ointment to be applied on the eyebrow twice daily.

    Other: Ointment vehicle

Interventions

  • Ointment containing LEO 124249

  • OtherOintment vehicle

    Ointment without active ingredients

06

What researchers measure

Primary outcomes

  1. Change from baseline to week 12 of investigator evaluated overall area score (ASoverall L+R) of eyebrow hair growth.

    The percentage area of the identified left and right eyebrow area and left and right region of interest (ROI) covered by hair growth will be scored according to the following: 1-10 % - 1 11-20 % - 2 21-30 % - 3 31-40 % - 4 41-50 % - 5 51-60 % - 6 61-70 % - 7 71-80 % - 8 81-90 % - 9 91-100 % - 10

    Time frame: baseline to week 12

Secondary outcomes

  1. Treatment emergent AEs (including AEs relating to local tolerability)

    Time frame: baseline to week 12

  2. Degree of response in change from baseline to Week 12 for ASoverall L+R

    Complete response - ≥ 8 Partial response - 4-\<8 Minimal response - 1-\<4 No response - \<1

    Time frame: baseline to Week 12

  3. Investigator evaluation of cosmetic outcome at Week 12 as assessed by Cosmetic outcome Score

    Is the appearance of the eyebrows cosmetically normal and acceptable? Yes - 1 No - due to insufficient regrowth area - 2 No - due to insufficient density - 3 No - due to uneven distribution - 4 No - due to other reason (explain, including combination of the above) - 5

    Time frame: baseline to Week 12

07

Study locations

2 sites
  • Investigational site
    Aarhus, 8000, Denmark
  • Investigational site
    Gentofte, 2820, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in May 2018, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2017
First posted
Oct 30, 2017
StartActual
Oct 30, 2017
Primary completionActual
May 16, 2018
CompletionActual
May 16, 2018
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03325296
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Oct 30, 2017
Start date
Oct 30, 2017
Primary completion
May 16, 2018
Completion
May 16, 2018
Last update
Feb 24, 2025

Study contacts

Study Director
study director · LEO Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion